User:Ahmed Zaghw: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(15 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Idiopathic interstitial pneumonia]]
Ahmed Zaghw is an '''ECFMG''' -certified physician and working as an associate medical editor in '''WikiDoc''' and research fellow at '''PERFUSE Study Group''', Harvard Medical School.


[[Sepsis resident survival guide]]
[[File:Ahmed Zaghw,MD Wiki resolution.jpg|right]]


[[Resident survival guide topics]]
==Education==


[[Interstitial lung disease]]
* '''Ain-Shams University, Cairo, Egypt''' (2003-2011)
** Baccalaureus of Medicine and Surgery MB BCh with “Excellence with Honor”


* '''Kentucky University, KY, USA'''
** Health care financial management and Clinical Leadership Management courses (2008)


{|class="wikitable"
==Work Experience==
|lolo||lolo2||lolo3
|-
|koko1||koko2||koko3
|-
|}


---
* Associate medical editor in WikiDoc.(2013)
{|class="wikitable" width="80%"
* Primary care physician in Medically Underserved Districts (MUDs) (2011-2012)
|lolo||lolo2||lolo3
|-
|koko1||koko2||koko3
|-
|}


==Research Experience==


----
* '''Kentucky University, KY, USA'''
{|class="wikitable"width="80%"
** Research Assistant in "Forearm Wearable Artificial Kidney" (2008)
|-
| colspan="1" style="text-align:center; background:"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor=""|<nowiki>"</nowiki>'''1. '''High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
| bgcolor=|<nowiki>"</nowiki>'''2. '''In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|}


* '''Ain-Shams University, Cairo, Egypt''' (2008-2009)
** Research trainee in Ain-Shams Stem Cell Group


{|style="width:80%; height:100px" border="1"
==Awards and Affiliation==
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | No underlying causes
|-
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Dental'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Dermatologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Drug Side Effect'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Ear Nose Throat'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Endocrine'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Environmental'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Gastroenterologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Genetic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Hematologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Iatrogenic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Infectious Disease'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Musculoskeletal/Orthopedic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Neurologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Nutritional/Metabolic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Obstetric/Gynecologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Oncologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Ophthalmologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Overdose/Toxicity'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Psychiatric'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Pulmonary'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Renal/Electrolyte'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Rheumatology/Immunology/Allergy'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Sexual'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Trauma'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Urologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Miscellaneous'''
|bgcolor="Beige"| No underlying causes
|-
|}
<table>
{|class="wikitable" border="1" style="text-align:center; width:600px;"
|-style="background:#CDC9C9"
| Risk category
| LDL goal, mg/dL
|Non-HDL goal, mg/dL
|-
| CHD and CHD risk equivalent (10 year risk for CHD is >20%)
| < 100
| < 130
|-
| Multiple (2+) risk factor (10 year risk for CHD is <20%)
| < 130
| < 160
|-
| 0-1 risk factors
| < 160
| < 190
|-
|}


ATP III LDL cholesterol and Non-HDL cholesterol goals <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref>
* '''ECFMG''' Certification (2013)
* “'''Best Research Reward'''” presented by Egyptian in 18th Ainshams International Medical Students Congress (AIMSC 2009), for the oral presentation '''The role of stem cell in cardiology-many ways to one goal'''
*Member of PADI, Professional American Diving Institute
*Member of Master Swimming Team for Tanta Sports Club


==WikiDoc contribution==
* Microchapters editing in cardiology, pulmonology and critical Care
:*[[Idiopathic interstitial pneumonia]]
:*[[Endocarditis antimicrobial treatment]]
:*[[Endocarditis other test]]
:*[[Pericarditis treatment]]
:*[[Gastrointestinal bleeding risk factors]]
:*[[Cardiogenic shock diagnostic evaluation]]
:*[[Atrial septal defect percutaneous closure]]
* Resident Survival Guide
:*[[Sepsis resident survival guide|Sepsis]]
:*[[Cardiogenic shock resident survival guide]]
:*[[Basic physical principles of ultrasound]]


{|class="wikitable" width="80%"
*Board Review Questions
|-
:*[[WBR1033]], [[WBR1034]], [[WBR1035]], [[WBR1036]], [[WBR1037]], [[WBR1038]], [[WBR1039]], [[WBR1040]], [[WBR1041]], [[WBR1042]], [[WBR1043]], [[WBR1044]], [[WBR1045]], [[WBR1046]], [[WBR1047]], [[WBR1048]], [[WBR1049]], [[WBR1050]]
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): <BR>
* Use high-intensity statin therapy unless contraindicated. <BR>


* For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
==Languages==
|-
|}


==References==
*Arabic: Fluent in speaking and writing
{{Reflist|2}}
*English: Fluent in speaking and writing
*German: Very good in speaking and writing
 
==Contact Information==
 
E-mail address: azaghw@bidmc.harvard.edu , ahmedzaghw@wikidoc.org
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 20:03, 6 February 2014

Ahmed Zaghw is an ECFMG -certified physician and working as an associate medical editor in WikiDoc and research fellow at PERFUSE Study Group, Harvard Medical School.

Education

  • Ain-Shams University, Cairo, Egypt (2003-2011)
    • Baccalaureus of Medicine and Surgery MB BCh with “Excellence with Honor”
  • Kentucky University, KY, USA
    • Health care financial management and Clinical Leadership Management courses (2008)

Work Experience

  • Associate medical editor in WikiDoc.(2013)
  • Primary care physician in Medically Underserved Districts (MUDs) (2011-2012)

Research Experience

  • Kentucky University, KY, USA
    • Research Assistant in "Forearm Wearable Artificial Kidney" (2008)
  • Ain-Shams University, Cairo, Egypt (2008-2009)
    • Research trainee in Ain-Shams Stem Cell Group

Awards and Affiliation

  • ECFMG Certification (2013)
  • “Best Research Reward” presented by Egyptian in 18th Ainshams International Medical Students Congress (AIMSC 2009), for the oral presentation The role of stem cell in cardiology-many ways to one goal
  • Member of PADI, Professional American Diving Institute
  • Member of Master Swimming Team for Tanta Sports Club

WikiDoc contribution

  • Microchapters editing in cardiology, pulmonology and critical Care
  • Resident Survival Guide
  • Board Review Questions

Languages

  • Arabic: Fluent in speaking and writing
  • English: Fluent in speaking and writing
  • German: Very good in speaking and writing

Contact Information

E-mail address: azaghw@bidmc.harvard.edu , ahmedzaghw@wikidoc.org


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=User:Ahmed_Zaghw&oldid=939592"